Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YKYY017 for inhalation in mild to moderate COVID-19 (Phase II/III)
ChiCTR2300075467Phase 3Recruiting
- Sponsor
- China-Japan Friendship Hospital
- Start
- Sep 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of YKYY017 in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by China-Japan Friendship Hospital. Primary endpoint: Time from start of treatment to sustained clinical recovery. Started Sep 2023; status: recruiting.
02
Drugs
YKYY017
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2300075467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075467.